Orthostatic Hypotension Market Report 2026

The orthostatic hypotension market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.17 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to aging population growth, rise in neurological disorders, increased cardiovascular disease prevalence, expansion of diagnostic testing, higher clinical awareness.

The orthostatic hypotension market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growth in remote monitoring adoption, rising chronic disease burden, expansion of specialty neurology care, increased screening programs, telehealth integration growth. Major trends in the forecast period include wearable blood pressure monitoring, autonomic function digital testing, remote patient monitoring programs, combination drug therapy protocols, home based hypotension care models.

The increasing incidence of neurodegenerative disorders is anticipated to drive the expansion of the orthostatic hypotension market in the coming years. Neurodegenerative disorders are progressive diseases marked by the degeneration of nerve cells in the brain and nervous system, resulting in motor and cognitive dysfunction. The frequency of neurodegenerative disorders is rising due to aging populations, as a growing number of people reach ages when conditions such as Alzheimer’s and Parkinson’s disease are more prevalent. The escalation of neurodegenerative disorders, including Parkinson’s disease and multiple system atrophy, contributes to the onset of orthostatic hypotension by disrupting autonomic nervous system regulation, impairing baroreceptor reflexes, and lowering vascular tone, thereby weakening the body’s capacity to maintain blood pressure when standing. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit health organization, reported that roughly 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating this number will increase to 13.8 million by 2060. Consequently, the rising incidence of neurodegenerative disorders is fueling growth in the orthostatic hypotension market.

The growing prevalence of cardiovascular diseases is expected to boost the expansion of the orthostatic hypotension market in the future. Cardiovascular diseases encompass conditions that affect the heart and blood vessels, including coronary heart disease, stroke, heart failure, and arrhythmias. The prevalence of these conditions is increasing with aging populations, as older age significantly heightens the likelihood of developing heart and vascular diseases, particularly among individuals over 65 years. The rising occurrence of cardiovascular diseases drives demand for orthostatic hypotension management, as patients with heart conditions face significantly greater risks of postural blood pressure irregularities requiring specialized monitoring and treatment. For instance, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023 cardiovascular disease caused 919,032 deaths, accounting for approximately one-third of all fatalities. Coronary heart disease remained the most prevalent type, with nearly one in six cardiovascular deaths occurring in adults under 65. Therefore, the increasing prevalence of cardiovascular diseases is contributing to the growth of the orthostatic hypotension market.

Key companies operating in the orthostatic hypotension market are focusing on developing innovative products such as wearable cerebral blood flow monitors to improve real-time symptom tracking and personalized patient care. A wearable cerebral blood flow monitor is a device worn on the body, such as in the ear, that measures blood flow to the brain in real time, helping detect orthostatic changes, predict fainting, and guide symptom management. For example, in June 2023, STAT Health, a US-based digital health startup, launched its ear-worn wearable device, designed specifically for orthostatic conditions. The device captures cerebral blood flow through a shallow ear artery, detects postural changes, and generates trend scores to help users track their time spent upright and blood flow abnormalities. Unique features include predictive fainting alerts, integration with a companion app, and long-term wearability combined with clinical-grade signal quality, enabling patients with conditions such as POTS, long COVID, and chronic fatigue syndrome to better manage their symptoms.

Major companies operating in the orthostatic hypotension market are Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories Ltd., Cipla Limited, H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Alembic Pharmaceuticals Ltd., Theravance Biopharma Inc., Avadel Pharmaceuticals plc, Civica Rx Inc., Alterity Therapeutics Limited, and STAT Health Services LLC.

Tariffs on diagnostic devices, monitoring equipment, and medical electronics are increasing procurement costs in the orthostatic hypotension market. Device based testing and monitoring segments are most affected. Import dependent healthcare systems face higher prices for tilt table and monitoring systems. These added costs can slow equipment upgrades in smaller facilities. At the same time, tariffs are encouraging domestic production of patient monitoring and diagnostic devices.

The orthostatic hypotension market research report is one of a series of new reports that provides orthostatic hypotension market statistics, including orthostatic hypotension industry global market size, regional shares, competitors with a orthostatic hypotension market share, detailed orthostatic hypotension market segments, market trends and opportunities, and any further data you may need to thrive in the orthostatic hypotension industry. This orthostatic hypotension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Orthostatic hypotension refers to a medical condition marked by a pronounced decrease in blood pressure when an individual moves from a sitting or lying position to standing. This abrupt drop in blood pressure can impair cerebral blood flow, causing symptoms such as dizziness, lightheadedness, blurred vision, or fainting. It frequently arises from impaired autonomic function, dehydration, medication effects, or underlying neurological or cardiovascular disorders.

The key components of the orthostatic hypotension market include fludrocortisone, midodrine hydrochloride, droxidopa, pyridostigmine, indomethacin, caffeine, epoetin, oxilofrine potassium chloride, and non-steroidal anti-inflammatory drugs (NSAIDs). Fludrocortisone is a synthetic corticosteroid used to expand blood volume and help manage symptoms of orthostatic hypotension. The market also covers various test types, such as ECG, blood tests, stress tests, and echocardiograms, and supports multiple routes of administration, including oral and parenteral. These drugs are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, with end users including hospitals, diagnostic centers, clinics, and ambulatory surgical centers.

The orthostatic hypotension market includes revenues earned by entities by providing services such as clinical diagnosis services, blood pressure monitoring services, autonomic function testing services, tilt table testing services, patient monitoring services, outpatient care services, inpatient care services, home healthcare services, telemedicine services, disease management services, rehabilitation services, clinical consultation services, and treatment management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.